Table 1.
Interactions with P-gp and BCRP for Approved and Study Drugs for Idiopathic Pulmonary Fibrosis*
| Status | Drug | P-gp | BCRP |
|---|---|---|---|
| Approved | |||
| Pirfenidone | Inhibitor | — | |
| Nintedanib | Substrate | — | |
| Phase 3 | |||
| Ambrisentan† | Substrate | — | |
| Bosentan† | Substrate | — | |
| Warfarin† | Inhibitor, substrate | — | |
| Imatinib† | Substrate | Substrate | |
| Sildenafil† | Inhibitor | — | |
| IFN-γ† | Inducer | — | |
| Trimethoprim‡§ | Inhibitor, inducer | — | |
| NAC† | — | — | |
| Phase 2 | |||
| Losartan | Substrate, inhibitor | — | |
| Prednisone‡ | Substrate, inhibitor | — | |
| Macitentan† | Inducer | — | |
| BG00011 (STX100) | — | — | |
| PRM-151 | — | — | |
| SAR156597 | — | — | |
| TD139 | — | — | |
| Treprostinil | — | — | |
| GLPG1690 | — | — | |
| Tetrathiomolybdate | — | — | |
| Zileuton | — | — | |
| Etanercept† | — | — | |
| BMS-986020† | — | — | |
| KD025‡ | — | — | |
| CC-90001‡ | — | — | |
| Compound 36 (GBT440)† | — | — | |
| PBI-4050 | — | — | |
| Tipelukast‡ | — | — | |
| Octreotide | — | — | |
| Azathioprine‡ | — | — | |
| QAX576 | — | — | |
| Phase 1 | |||
| Dasatanib | Substrate, inhibitor | — | |
| Vismodegib§ | Substrate | Inhibitor | |
| Sirolimus | Inhibitor, inducer | — | |
| Quercetinठ| Inhibitor | Inhibitor | |
| IW001 | — | — | |
| Nandrolone decanoate | — | — | |
| Omipalisib (GSK2126458) | — | — | |
| GSK3008348 | — | — | |
| Tanzisertib (CC-930)† | — | — | |
| Preclinical | |||
| Colchicine | Substrate, inhibitor, inducer | — | |
| Felodipine | Inhibitor | — | |
| Atorvastatin | Inhibitor | — | |
| Protectin DX | — | — | |
| Everolimus | — | — |
Definition of abbreviations: BCRP = breast cancer resistance protein; NAC = N-acetylcysteine; P-gp = permeability glycoprotein.
*
This table was compiled using DrugBank 5.0 (www.drugbank.ca), which is a comprehensive drug database supported by the Canadian Institutes of Health Research (40). This is not a list of all drugs in development as therapy for idiopathic pulmonary fibrosis.
†
Negative results.
‡
Currently recruiting participants (www.clinicaltrials.gov).
§
In a combination strategy.